Company: ANIX
Filing Date: 2025-09-10
Form Type: S-3
Source: 0001493152-25-013010
Chunk: 46

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: S-3
Chunk 46
---
 at all, and may depend on positive results from human clinical trials.

Corporate Information

Our principal executive offices are located at 3150 Almaden Expressway, Suite 250, San Jose, CA 95118, our telephone number is (408) 708-9808, and our Internet website address is https://www.anixa.com/. The information on our website is not a part of, or incorporated in, this prospectus.

| S-4 |

THE OFFERING

| Common                
 stock offered by us:  |     | Shares                                                                                                                                   
 of our common stock having an aggregate offering price of up to $100,000,000.                                                            |
| Manner                
 of offering           |     | “At                                                                                                                                      
 the market offering” that may be made from time to time through our sales agent, Cantor. See “Plan of Distribution”                      
 on page S-12 of this prospectus.                                                                                                         |
| Use                   
 of Proceeds           |     | We                                                                                                                                       
 intend to use the net proceeds from these sales, if any, for general corporate purposes, including, but not limited to, ongoing clinical 
 and pre-clinical work, the development of new cancer and other healthcare related technologies, investing in or acquiring companies      
 that are synergistic with or complementary to our technologies, and licensing activities related to our current and future product       
 candidates and working capital. See “Use of Proceeds” on page S-8 of this prospectus.                                                    |
| Risk                  
 Factors               |     | Your                                                                                                                                     
 investment in our securities involves substantial risks. You should consider the “Risk Factors” and the “Cautionary                      
 Note Regarding Forward-Looking Statements” included and incorporated by reference in this prospectus and the accompanying prospectus,    
 including the risk factors incorporated by reference from our filings with the SEC.                                                      |
| NASDAQ                
 Capital Market symbol |     | “ANIX”                                                                                                                                   |

| S-5 |

<div align='center'>RISK FACTORS</div>

Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully consider the risk factors we describe in this prospectus and in any related free writing prospectus that we may authorize to be provided to you or in any report incorporated by reference into this prospectus, including our Annual Report on Form 10-K for the year ended October 31, 2024, or any Annual Report on Form 10-K or Quarterly Report on Form 10-Q that